Send to

Choose Destination
J Gastrointest Oncol. 2016 Feb;7(1):143-57. doi: 10.3978/j.issn.2078-6891.2015.112.

Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future.

Author information

1 Kaiser Permanente, Fontana, CA, USA ; 2 Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.


Peritoneal carcinomatosis (PC) has historically been considered a terminal condition with merely palliative treatment achieving a survival rate measured in months. Cytoreductive surgery (CyRS) and intraperitoneal chemotherapy (IPC) have emerged as potentially effective regional treatments with the potential for long-term survival in well-selected patients. The fundamentals of CyRS and IPC are patient selection and complete cytoreduction. Since there is now sufficient evidence for the superiority of CyRS and IPC to systemic chemotherapy alone in a highly select group of patients, surgeons and oncologists should be aware of this modality as a potential benefit for patients with PC. The aim of this report is to highlight cancer-specific evidence in the context of ongoing studies regarding the outcome of this treatment.


Cytoreductive surgery (CyRS); appendiceal mucinous neoplasms; colorectal cancer (CRC); early postoperative intraperitoneal chemotherapy (EPIC); gastric cancer; hyperthermic intraperitoneal chemotherapy (HIPEC); intraperitoneal chemotherapy (IPC); ovarian cancer and mixed types of peritoneal cancer (OC and mixed types of peritoneal cancer); peritoneal carcinomatosis (PC); peritoneal mesothelioma

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center